Linden Advisors LP Makes New $6.55 Million Investment in Alnylam Pharmaceuticals, Inc. $ALNY

Key Points

• Linden Advisors LP established a new position in Alnylam, buying 14,364 shares in the 3rd quarter valued at approximately $6.55 million.
• Analyst sentiment is mixed but overall positive with a MarketBeat consensus of "Moderate Buy" and an average price target of $468.84, amid divergent broker moves (price-target cuts by Jefferies and Morgan Stanley and buys/raises from others).
• Company insiders have been net sellers recently, offloading 53,923 shares worth $18.07 million in the past 90 days, leaving insiders with about 1.20% ownership.

Linden Advisors LP bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report) during the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund bought 14,364 shares of the biopharmaceutical company's stock, valued at approximately $6,550,000.

A number of other institutional investors have also recently bought and sold shares of the stock. Brighton Jones LLC acquired a new position in Alnylam Pharmaceuticals in the 4th quarter worth $243,000. Geneos Wealth Management Inc. grew its stake in Alnylam Pharmaceuticals by 372.3% in the first quarter. Geneos Wealth Management Inc. now owns 222 shares of the biopharmaceutical company's stock valued at $60,000 after purchasing an additional 175 shares in the last quarter. Allworth Financial LP grew its stake in shares of Alnylam Pharmaceuticals by 11.8% in the second quarter. Allworth Financial LP now owns 691 shares of the biopharmaceutical company's stock valued at $225,000 after buying an additional 73 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in Alnylam Pharmaceuticals by 0.3% during the second quarter. PNC Financial Services Group Inc. now owns 13,170 shares of the biopharmaceutical company's stock worth $4,295,000 after buying an additional 45 shares during the last quarter. Finally, Cetera Investment Advisers increased its holdings in Alnylam Pharmaceuticals by 23.3% during the second quarter. Cetera Investment Advisers now owns 9,888 shares of the biopharmaceutical company's stock worth $3,224,000 after buying an additional 1,871 shares during the last quarter. Institutional investors own 92.97% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on ALNY. Jefferies Financial Group reiterated a "hold" rating and issued a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a research note on Monday. Oppenheimer began coverage on shares of Alnylam Pharmaceuticals in a research note on Wednesday, January 7th. They set an "outperform" rating and a $500.00 price objective on the stock. Stifel Nicolaus upped their target price on shares of Alnylam Pharmaceuticals from $495.00 to $508.00 and gave the company a "buy" rating in a report on Thursday, December 11th. Weiss Ratings upgraded shares of Alnylam Pharmaceuticals from a "sell (d-)" rating to a "hold (c-)" rating in a research note on Thursday, January 15th. Finally, Morgan Stanley lowered their price target on Alnylam Pharmaceuticals from $495.00 to $408.00 and set an "equal weight" rating on the stock in a research report on Friday, January 30th. One analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating and six have issued a Hold rating to the company's stock. According to data from MarketBeat, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $468.84.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, EVP Pushkal Garg sold 2,242 shares of the stock in a transaction dated Friday, February 13th. The shares were sold at an average price of $310.08, for a total value of $695,199.36. Following the transaction, the executive vice president directly owned 24,848 shares of the company's stock, valued at $7,704,867.84. This represents a 8.28% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Jeffrey V. Poulton sold 2,780 shares of the firm's stock in a transaction that occurred on Monday, January 12th. The stock was sold at an average price of $362.87, for a total transaction of $1,008,778.60. Following the sale, the executive vice president owned 57,465 shares of the company's stock, valued at $20,852,324.55. This trade represents a 4.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 53,923 shares of company stock valued at $18,072,087 in the last 90 days. Insiders own 1.20% of the company's stock.

Alnylam Pharmaceuticals Price Performance

NASDAQ:ALNY opened at $318.91 on Tuesday. Alnylam Pharmaceuticals, Inc. has a one year low of $205.87 and a one year high of $495.55. The company has a market cap of $42.29 billion, a P/E ratio of 186.50 and a beta of 0.36. The firm's fifty day moving average price is $342.78 and its two-hundred day moving average price is $408.50. The company has a debt-to-equity ratio of 1.28, a current ratio of 2.76 and a quick ratio of 2.71.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last posted its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.43 by ($0.18). The company had revenue of $1.10 billion for the quarter, compared to analyst estimates of $1.16 billion. Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The business's quarterly revenue was up 84.9% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.65) EPS. Equities analysts expect that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc NASDAQ: ALNY is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.

Want to see what other hedge funds are holding ALNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.